Selective C-reactive protein apheresis in acute myocardial infarction: rationale and design of a prospective
Jan Torzewski1, Stephan Mattecka2, Benjamin Mayer3
1Cardiovascular Center Oberallgaeu-Kempten, Clinic Association Allgaeu, Kempten.
Insights
C-reactive protein (CRP) apheresis shows promise for treating acute myocardial infarction (AMI). A new trial will assess its safety and efficacy in reducing cardiovascular death or heart failure hospitalizations.
Area of Science:
- Cardiology
- Immunology
- Biomedical Engineering
Background:
- C-reactive protein (CRP) is a key inflammatory marker and therapeutic target in acute myocardial infarction (AMI).
- Emerging evidence from pilot studies suggests CRP apheresis is effective in various cardiovascular conditions, including COVID-19 and acute coronary syndromes.
Purpose of the Study:
- To outline the design of a pivotal international randomized controlled trial for CRP apheresis in AMI.
- To establish the safety and efficacy of CRP apheresis in reducing major adverse cardiovascular events in AMI patients.
Main Methods:
- The study proposes a randomized controlled trial design.
- Key endpoints include cardiovascular mortality and rehospitalization for heart failure.
- Statistical methodology for analyzing trial data is detailed.
Main Results:
- Pilot data indicate promising outcomes for CRP apheresis in cardiovascular diseases.
- The proposed trial aims to provide robust evidence for CRP apheresis in AMI.
Conclusions:
- CRP apheresis is a potential therapeutic strategy for improving outcomes in acute myocardial infarction.
- The planned trial will determine the clinical utility of CRP apheresis in AMI management.
Background:
C-reactive protein (CRP) has long been identified as a potential therapeutic target to improve outcomes in acute myocardial infarction (AMI). Recently, CRP apheresis has shown promising results from first-in-human case reports, registries, and pilot trials in patients with COVID-19, acute ST-segment elevation myocardial infarction, cardiogenic shock, and non-ST-segment elevation acute coronary syndromes.
Methods And Results:
Herein we describe the perspective for a pivotal, international, randomized controlled trial investigating CRP apheresis in AMI. We herein propose the rationale, design, endpoints, and statistical methodology of this study.
Conclusion:
The goal is to demonstrate the safety and efficacy of CRP apheresis in AMI in reducing the combined primary clinical endpoint of cardiovascular mortality or rehospitalization for heart failure.
More Related Videos
10:03Coronary Progenitor Cells and Soluble Biomarkers in Cardiovascular Prognosis after Coronary Angioplasty
Published on: January 28, 2020
05:41Left Anterior Descending Coronary Artery Ligation for Ischemia-Reperfusion Research: Model Improvement via Technical Modifications and Quality Control
Published on: December 16, 2022
Related Concept Videos
01:20Blood Studies for Cardiovascular System I: Cardiac Biomarkers
The essential diagnostic tools for detecting myocardial necrosis and monitoring individuals suspected of having acute coronary syndrome (ACS) include:
Troponins
Troponins, particularly cardiac troponins I and T, are the most precise and sensitive markers of myocardial injury. They are detectable within 4-6 hours of myocardial injury and remain...
01:19Blood Studies for Cardiovascular System II: CRP, Hcy, and Cardiac Natriuretic Peptide Markers
These markers indicate stress or strain on the heart muscle:
Natriuretic Peptides (BNP)
Cardiac myocytes produce these hormones in response to ventricular stretching...